Johnson & Johnson $JNJ Stock Position Decreased by Horizon Investments LLC

Key Points

• Horizon Investments LLC trimmed its Johnson & Johnson stake by 3.3% in Q4, selling 7,661 shares and leaving it with 227,420 shares valued at about $47.07 million (JNJ is 0.6% of its portfolio and its 26th largest holding).
• JNJ beat Q1 estimates with $2.70 EPS on $24.06 billion in revenue (revenue up 9.9% YoY), issued FY2026 guidance of $11.45–11.65 EPS, and raised its quarterly dividend to $1.34 (annualized $5.36, ~2.4% yield).
• Analysts remain generally positive: multiple firms raised price targets (e.g., Citigroup to $285, Argus to $275, HSBC to $280), and the consensus rating is a Moderate Buy with a $252.48 consensus target.

Horizon Investments LLC cut its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 3.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 227,420 shares of the company's stock after selling 7,661 shares during the quarter. Johnson & Johnson accounts for 0.6% of Horizon Investments LLC's portfolio, making the stock its 26th largest holding. Horizon Investments LLC's holdings in Johnson & Johnson were worth $47,065,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also modified their holdings of JNJ. WealthCollab LLC grew its position in shares of Johnson & Johnson by 4.7% in the fourth quarter. WealthCollab LLC now owns 1,015 shares of the company's stock valued at $210,000 after purchasing an additional 46 shares during the last quarter. Vista Investment Partners II LLC grew its position in Johnson & Johnson by 1.2% during the fourth quarter. Vista Investment Partners II LLC now owns 3,811 shares of the company's stock worth $789,000 after buying an additional 47 shares in the last quarter. Campbell Deegan Wealth Management LLC grew its position in Johnson & Johnson by 1.6% during the fourth quarter. Campbell Deegan Wealth Management LLC now owns 2,990 shares of the company's stock worth $619,000 after buying an additional 48 shares in the last quarter. Finivi Inc. lifted its stake in Johnson & Johnson by 2.0% during the fourth quarter. Finivi Inc. now owns 2,458 shares of the company's stock worth $509,000 after purchasing an additional 48 shares during the period. Finally, Centennial Wealth Advisory LLC lifted its stake in Johnson & Johnson by 2.2% during the fourth quarter. Centennial Wealth Advisory LLC now owns 2,284 shares of the company's stock worth $473,000 after purchasing an additional 49 shares during the period. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Trading Down 1.3%

JNJ opened at $224.15 on Tuesday. The stock has a market capitalization of $539.57 billion, a P/E ratio of 25.91, a P/E/G ratio of 2.23 and a beta of 0.27. Johnson & Johnson has a 12 month low of $146.12 and a 12 month high of $251.71. The firm's fifty day simple moving average is $238.83 and its 200 day simple moving average is $219.90. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.46.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, April 14th. The company reported $2.70 EPS for the quarter, beating the consensus estimate of $2.68 by $0.02. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The business had revenue of $24.06 billion for the quarter, compared to analysts' expectations of $23.60 billion. During the same period in the previous year, the firm posted $2.77 EPS. The firm's revenue was up 9.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. As a group, research analysts anticipate that Johnson & Johnson will post 11.57 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th will be given a dividend of $1.34 per share. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.30. The ex-dividend date of this dividend is Tuesday, May 26th. This represents a $5.36 annualized dividend and a yield of 2.4%. Johnson & Johnson's payout ratio is presently 60.12%.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA wins and regulatory progress could boost future revenue for JNJ’s rare‑disease and schizophrenia programs; the article discusses how investors may respond to those approvals. How Investors May Respond To Johnson & Johnson (JNJ) New FDA Wins In Rare Disease And Schizophrenia
• Positive Sentiment: JNJ’s CAPLYTA (lumateperone) ranked highest in a network meta‑analysis for adjunctive MDD efficacy and showed no weight gain versus placebo — a favorable positioning for psychiatry sales and prescribing. CAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments
• Positive Sentiment: FDA accepted a protocol amendment for the NANORAY‑312 Phase 3 head & neck cancer trial sponsored by JNJ (Nanobiotix program) — regulatory acceptance reduces an execution risk for a partnered oncology asset. Nanobiotix Announces Protocol Amendment to Ongoing Global Phase 3 Head and Neck Cancer Study
• Positive Sentiment: A J&J study supports use of Abiomed’s Impella 5.5 in non‑shock, high‑risk patients, which may help device adoption and hospital use cases relevant to JNJ’s devices/solutions exposure. Johnson & Johnson study backs Abiomed Impella 5.5 in non-shock, high-risk patients
• Neutral Sentiment: Wall Street analysts remain moderately optimistic on JNJ after recent performance — supportive but not a catalyst by itself. Are Wall Street Analysts Bullish on Johnson & Johnson Stock?
• Neutral Sentiment: Investor letters and coverage (Baron/InsiderMonkey pieces) argue JNJ’s accelerating growth justifies a higher multiple — positive for medium‑term thesis but highlights valuation sensitivity. Johnson & Johnson’s (JNJ) Accelerating Growth Justifies the Higher Multiple
• Negative Sentiment: Sector dynamics: AbbVie’s strong Q1 results and raised guidance have lifted ABBV shares, which can divert investor funds within the healthcare group and pressure JNJ’s relative performance today. ABBV Stock Up 5% on Robust Q1 Performance: Time to Buy, Sell or Hold?

Analysts Set New Price Targets

A number of research analysts have commented on JNJ shares. Citigroup raised their price target on shares of Johnson & Johnson from $274.00 to $285.00 and gave the stock a "buy" rating in a research note on Tuesday, April 7th. Wall Street Zen cut shares of Johnson & Johnson from a "buy" rating to a "hold" rating in a research report on Saturday, February 14th. Argus upped their target price on shares of Johnson & Johnson from $240.00 to $275.00 and gave the company a "buy" rating in a research report on Thursday, April 16th. HSBC upped their target price on shares of Johnson & Johnson from $265.00 to $280.00 and gave the company a "buy" rating in a research report on Tuesday, March 17th. Finally, TD Cowen initiated coverage on shares of Johnson & Johnson in a research report on Wednesday, April 8th. They issued a "buy" rating and a $250.00 price objective on the stock. Eighteen investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $252.48.

Insider Activity

In other Johnson & Johnson news, EVP Vanessa Broadhurst sold 6,197 shares of the business's stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the sale, the executive vice president directly owned 23,003 shares of the company's stock, valued at $5,598,700.17. The trade was a 21.22% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Timothy Schmid sold 1,322 shares of the business's stock in a transaction dated Friday, February 20th. The stock was sold at an average price of $245.66, for a total transaction of $324,762.52. Following the sale, the executive vice president directly owned 25,447 shares in the company, valued at $6,251,310.02. This trade represents a 4.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 30,142 shares of company stock worth $7,360,528 over the last three months. Insiders own 0.16% of the company's stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.